View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 14, 2020updated 12 Jul 2022 11:57am

Atreca doses first patient in Phase Ib trial of oncology drug

Biotechnology company Atreca has dosed the first patient in a Phase Ib clinical trial evaluating monoclonal antibody ATRC-101 for the treatment of select solid tumour cancers.

Biotechnology company Atreca has dosed the first patient in a Phase Ib clinical trial evaluating monoclonal antibody ATRC-101 for the treatment of select solid tumour cancers.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Patients with colorectal, ovarian, non-small cell lung and breast cancers and acral melanoma will be enrolled for the first-in-human open-label, dose-escalation, monotherapy trial with an adaptive 3+3 design.

The company evaluated tumour tissue samples in each of these cancer types and found that more than 50% were positive for the antigenic target of ATRC-101.

Atreca CEO John Orwin said: “Dosing of the first patient in our Phase Ib study of ATRC-101 is an important milestone marking our transition to a clinical-stage company.

“ATRC-101 has demonstrated potent single-agent anti-tumour activity in multiple preclinical solid tumour models and we believe, through both its novel target and mechanism of action, that this antibody represents an exciting potential new approach in oncology.”

The trial aims to characterise ATRC-101’s safety and determine a recommended dose for future studies.

Potential biomarkers and initial signals of clinical activity of ATRC-101 will be evaluated as part of the trial.

Once safety is confirmed, Atreca plans to test the drug as a single agent and in combination with checkpoint inhibitors and select chemotherapeutics.

The company plans to release the initial data from this study in the second half of this year.

ATRC-101 is derived from a human antibody identified in a cancer patient through Atreca’s drug discovery platform.

The drug targets a ribonucleoprotein (RNP) complex and is believed to function through the Driver Antigen Engagement mechanism.

Last December, Atreca secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for ATRC-101.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena